NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.

In a research note published last night Bhalla said that Citi has upped its FY 2013 EPS estimate for Agilent to $3.04 from $3.00 and FY 2014 EPS estimate to $3.40 from $3.29. He also said he believes Agilent will produce organic revenue growth of 4 percent to 5 percent for 2014 and 2015, rather than the 3 percent originally modeled by the bank.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.